PharmaQMtraining.eu
Course Outline
 
   
A Short Course on Regulatory Affairs with emphasis on the
Background, Content and Detail of Module 3 of the Common Technical Document (CTD), the ‘Quality Module’
TIMETABLE (tentative)

27 July 2011
Registration
09.30h
Day 1 Start
10.00h
Finish
18.00h
 
Dinner
19.15h
28 July 2011
Day 2 Start
08.45h
Finish
16.30h
INTRODUCTION AND WELCOME

INTRODUCTION TO THE INTERNATIONAL CONFERENCE ON HARMONISATION (ICH)

  • ICH, its guidelines and the Common Technical Document (CTD)
  • CTD Module 2.3 and Module 3

INTRODUCTION TO THE EUROPEAN REGULATORY SYSTEM:

  • EU and Council of Europe operations and regulatory tasks
  • Pharmaceutical legislation
  • EU guidelines
  • The European Pharmacopoeia
INTRODUCTION TO THE ACTIVITIES AND INFLUENCE OF THE EUROPEAN PHARMACOPOEIA
THE PURPOSE, FORMAT AND CONTENT OF THE QUALITY OVERALL SUMMARY, CTD MODULE 2.3

STARTING TO BUILD CTD MODULE 3

  • Understanding how the legislation, official guidelines, European Pharmacopoeia and other Council of Europe publications shape the required content of CTD Module 3

UNDERSTANDING DRUG SUBSTANCE ISSUES AND CONTRIBUTIONS TO CTD MODULE 3

  • Sourcing of drug substances, GMP, vendor verification, pedigree, QP certification
  • Starting and other materials in a chemical synthesis
  • Chemistry development issues: characterisation, analytical validation, specifications and their justification
  • Data provision options for manufacturing and control including Master Files and Certificates of Suitability
  • ‘Conventional’ organic impurities
  • Other impurities: residual solvents, residues of metal catalysts and reagents, inorganic impurities, genotoxic impurities, enantiomeric impurities
  • Stability
  • Specifications

UNDERSTANDING DRUG PRODUCT (DOSAGE FORM) ISSUES AND CONTRIBUTIONS TO CTD MODULE 3

  • Starting and other materials in drug formulation
  • Pharmaceutical development: composition, functions, optimisation, performance, bioequivalence
  • Manufacturing process         
  • In-process and end-product control including specifications and their justification
  • Stability
  • Numerous examples
  • Common deficiencies
Group Interactive Mini-Workshop #1     
THE DRUG SUBSTANCE
Group Interactive Mini-Workshop #2   
PHARMACEUTICAL DEVELOPMENT
Previous page

EXCEPTIONAL VALUE: £995.00 + VAT

High-quality, carefully-structured training, accommodation for one night*, one breakfast, two lunches and a conference dinner, daytime in-course refreshments, a substantial delegates manual to reinforce the learning experience and a certificate of attendance
[14h Continuing Professional Development (CPD)]
* extra night(s) bookable if required, subject to availability

MORE ABOUT THE BACKGROUND TO THIS COURSE
AND WHO SHOULD ATTEND

This Course will be a comprehensive and group interactive course that builds from first principles and explores numerous pharmaceutical topics that have to be addressed in supporting documentation for Marketing Authorisation Applications (MAAs). 

The course has been well developed over many years and has been highly regarded by delegates of varied experience in regulatory affairs and associated departments. Past delegates have been and future ones are expected to be from within the pharmaceutical and chemical industries (chemical development, analytical, formulation and pharmaceutical development, manufacturing, regulatory/registration departments) and the Competent Authorities (assessors, inspectors, scientific/medical writers).

The course is suitable for people new or relatively new to regulatory affairs, particularly people transferring within a company into product registration work, and for those needing a refresher course or an up-to-date understanding of CTD Module3.

COURSE LEADERS

The trainers will be Professor Derek Calam, Paul Fleming and Dr Mike Robertson who between them have many years of experience within UK, European and WHO institutions and have reviewed numerous MAAs.

Book here

Please sign up for future announcements

Previous page